01:59

Whole body-MRI and fluorine 18 fluorodeoxyglucose PET/CT shows promising diagnostic accuracy in ...

04:35

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia

02:38

ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promye...

03:23

Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms

04:34

EHA 2024: Multiple myeloma roundup

03:27

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to...

04:59

Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphobla...

02:40

More effective treatment options required for patients with MM post lenalidomide exposure

04:10

Ibrutinib and venetoclax continue to provide benefits for patients with chronic CLL and SLL

05:24

Lower levels of inflammatory markers and tumour burden is linked to improvements in PFS with Ide...

02:29

Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL/SLL with del(17p) a...

06:26

Encouraging results using mismatched unrelated donors in stem cell transplantation

06:04

Immunotherapy significantly increases the number of patients free from bowel cancer

02:26

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant ...

02:32

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cance...

04:35

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-...

02:57

Osimertinib poised to change standard of care treatment for patients with locally advanced EGFR-...

05:00

Transoral surgery and neck dissection with deintensified risk-based post-operative management re...

03:48

Immune therapy with belantamab mafodotin and elotuzumab shows encouraging safety profile and pre...

01:47

Chemotherapy before and after surgery may be new standard treatment for some patients with oesop...

04:33

Durvalumab following chemoradiotherapy improves survival in patients with limited-stage small-ce...

02:52

Teclistamab continues to demonstrate deep and durable responses in relapsed/refractory multiple ...

05:26

ASCO 2024: Lung cancer roundup

05:30

Cancer advocacy and fundraising in Nigeria

03:12

Neoadjuvant daromun is an effective and safe therapeutic option for resectable, locally advanced...

05:00

Advanced epithelial ovarian cancer patients may safely avoid a lymphadenectomy without it impact...

06:37

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy ...

04:01

Addition of cabazitaxel to abiraterone/prednisone significantly prolonged PFS in extensive disea...

02:57

Neoadjuvent ipilimumab plus nivolumab beneficial compared to adjuvent nivolumab in macroscopic, ...

04:40

Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with NDMM...

04:41

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-p...

04:07

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant br...

04:34

Neoadjuvant sacituzumab govitecan showed promising activity in muscle-invasive urothelial bladde...

02:54

Results from first safety run-in demonstrate a manageable safety profile with early efficacy of ...

04:26

Maintenance systemic therapy versus local consolidative therapy plus maintenance systemic therap...

04:11

Inavo, palbo plus fulv sees sustained benefit beyond disease progression in HER2‑negative locall...

02:26

Adagrasib demonstrates improvement in PFS and ORR over docetaxel in patients with previously tre...

02:48

Clinical behaviour of breast cancer in young BRCA carriers and prognostic impact of the timing o...

03:57

Bortezomib and dexamethasone demonstrate efficacy benefit in key subgroups vs daratumumab, borte...

03:04

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy

03:48

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed...

02:27

Monitoring ovarian function in oncology studies

03:48

Ciltacabtagene autoleucel improves outcomes in patients with len-refractory FHR MM

06:13

Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas

04:52

Telehealth delivery of palliative care an effective alternative to in-person visits for patients...

04:34

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma

04:25

Trial arguing strongly for the development of 1st-line biomarker selected strategies in pancreat...

02:22

PD-1–refractory advanced melanoma: how do we get to the finish line?

02:34

Highlights in melanoma from ASCO 2024

01:28

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab ...

04:03

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated w...

09:05

Quality of life and patient satisfaction of Filipinos after breast conservation surgery and intr...

52:43

Cost-benefit analysis of new cancer medicines: The difficult choices of governments

52:21

Grand Rounds: Improving quality of patient-centred care

03:32

HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients ...

03:16

CAR-T, bispecifics or ADCs in late-stage RRMM

02:44

Complementing clinical trials: Investigating the value of real world evidence with insights from...

02:11

Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET/CT and whole-body...

10:03

Treatment of multiple myeloma in Turkey

04:47

Melflufen and dexamethasone versus pomalidomide and dexamethasone in relapsed refractory multipl...